
Evolent Health (EVH) Stock Forecast & Price Target
Evolent Health (EVH) Analyst Ratings
Bulls say
Evolent Health Inc. is poised for continued growth, supported by its leadership in specialty-focused value-based care and a track record of exceeding its mid-teens revenue growth target. The company has secured an expected EBITDA improvement of $100 million to $105 million for 2025 through successful Performance Suite negotiations, which will enhance its financial stability and operational efficiency despite some adjustments to product features. Furthermore, the anticipated resilience in Medicaid membership and the expedited timeline to mature margins—projected at 18-24 months—underscore a positive outlook for Evolent Health's financial performance moving forward.
Bears say
Evolent Health Inc. faces significant challenges regarding its membership outlook, as indicated by Humana's revised expectations of a decline of 550,000 in individual MA membership for 2025, which could adversely affect Evolent's own membership associated with Humana. Additionally, the company's client, Florida Blue, is experiencing a membership drop of approximately 35,000, contributing to a broader expectation of reduced revenue prospects through lowered EBITDA estimates for Q4 and into FY25. Furthermore, the company is anticipating headwinds from a declining Medicare membership base, with projections showing a decrease from 250,000 members at year-end 2024 to roughly 217,000 as they enter 2025, which undermines revenue growth potential.
This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.
Evolent Health (EVH) Analyst Forecast & Price Prediction
Start investing in Evolent Health (EVH)
Order type
Buy in
Order amount
Est. shares
0 shares